Monday 1 July 2024

The Pharma Letter Podcast — Episode 22 — A new way to innovate, from Flagship Pioneering

Biotechnology
Simon Wentworth
20 April 2023
episode22-big-1

More on this story...

Pharmaceutical
Novo Nordisk wraps up another weight management deal
9 May 2024
Biotechnology
AbbVie's Michael Severino joining Flagship Pioneering as CEO-Partner
13 April 2022
Biotechnology
Another $273 million for well-funded Flagship firm using AI
14 September 2023
Biotechnology
Flagship Pioneering unveils new company Quotient Therapeutics
22 November 2023


Related Company News

India's PLI scheme sets stage for semaglutide production in 2026
The week in pharma: action, reaction and insight – week to June 28, 2024
Novo Nordisk stops ocedurenone CLARION-CKD trial
EU taking action to tackle GLP-1 receptor agonist shortages
More ones to watch >


Today's issue

Pharmaceutical
Boosting crinecerfont, Neurocrine draws from gamut of FDA support
1 July 2024
Biotechnology
Forbion expands to Boston, hires former Dyne CEO
1 July 2024
Pharmaceutical
In ALS, Phase II data show two drugs could be better than one
1 July 2024
Biotechnology
Another win for nipocalimab as J&J closes in on rivals
1 July 2024
Pharmaceutical
Merck & Co sees value in novel prostate cancer drug
1 July 2024
Biotechnology
New Ajovy data challenges treatment breaks in migraine prevention
1 July 2024
Biotechnology
Zenas BioPharma appoints Orlando Oliveira as CCO
1 July 2024

Company Spotlight

A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.




More Features in Biotechnology

Forbion expands to Boston, hires former Dyne CEO
1 July 2024
Another win for nipocalimab as J&J closes in on rivals
1 July 2024
New Ajovy data challenges treatment breaks in migraine prevention
1 July 2024
Zenas BioPharma appoints Orlando Oliveira as CCO
1 July 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze